Related Experiment Video
Updated: Jun 18, 2025
04:34
Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
634
Gangliocytic paraganglioma: A case report
Álvaro Valverde Márquez1, Cristina Robles Lázaro1, José Antonio Muñoz León2
1Servicio de Endocrinología y Nutrición, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Endocrinologia, Diabetes Y Nutricion
|August 1, 2024
Summary
Gangliocytic paragangliomas (GPs) are rare duodenal neuroendocrine tumors. Surgical resection is the primary treatment, with radiotherapy considered for lymph node invasion.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Pathology
Background:
- Paragangliomas (PGLs) are rare neuroendocrine tumors (NET) originating from the adrenal gland or extra-adrenal paraganglia.
- Extra-adrenal PGLs can develop a gangliocytic component, forming gangliocytic paragangliomas (GPs), most commonly in the duodenum.
Observation:
- A 43-year-old patient presented with epigastric pain, nausea, and vomiting.
- CT scan revealed a duodenal nodular lesion.
- Ultrasound-guided Fine Needle Aspiration (FNA) showed neuroendocrine cells and neural tissue.
Findings:
- Surgical resection was performed as the primary treatment for the duodenal gangliocytic paraganglioma.
- Adjuvant radiotherapy was not administered due to the absence of lymphatic or pancreatic parenchyma invasion.
Implications:
- The management of GPs is not standardized and requires a multidisciplinary team approach.
- Surgical resection remains the cornerstone of GP treatment.
- Adjuvant radiotherapy may be considered in cases with confirmed lymph node invasion.
